NCT04747717 is a NA clinical trial of chemotherapy/surgery in Ovarian Cancer, sponsored by N.N. Petrov National Medical Research Center of Oncology.

Who is sponsoring NCT04747717?

NCT04747717 is sponsored by N.N. Petrov National Medical Research Center of Oncology.

What drugs are being tested in NCT04747717?

Interventions in NCT04747717: chemotherapy/surgery.

What condition does NCT04747717 study?

NCT04747717 studies Ovarian Cancer.

Is NCT04747717 still recruiting?

NCT04747717 is currently status unknown. Last updated 11 February 2021.

Last reviewed 2021-02-11 · How we verify

NCT04747717

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer

Status unknown NA Last updated 11 February 2021

What this trial tests

NA trial testing chemotherapy/surgery in Ovarian Cancer in 30 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
1 October 2022

1 October 2025

Quick facts

Lead sponsor	N.N. Petrov National Medical Research Center of Oncology
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 October 2020
Primary completion	1 October 2022
Estimated completion	1 October 2025
Sites	1 location across Russia

Drugs / interventions tested

chemotherapy/surgery

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

N.N. Petrov National Medical Research Center of Oncology — full company profile →

Who can join

Adults 18 to 75, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplatin (TP)).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of outcomes of neoadjuvant chemotherapy in <i>BRCA1</i>- versus <i>BRCA2</i>-associated breast and ovarian cancers.
Sokolenko A, Gorodnova T, Enaldieva D, Shestakova A, et al · · 2025 · cited 2× · PMID 40547808 · DOI 10.37349/etat.2025.1002325

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other N.N. Petrov National Medical Research Center of Oncology trials

Trials by the same sponsor.

NCT06418789 — High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors · Phase 2 · recruiting
NCT06133699 — Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors · NA · unknown
NCT06229340 — Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations · Phase 2 · recruiting
NCT06043947 — Survival Monitoring in Russian Cancer Registries · active not recruiting
NCT05468827 — ICG Fluorescence Guided Lymph Node Mapping for Determination of Bowel Resection Margins in Colon Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04747717 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by N.N. Petrov National Medical Research Center of Oncology
Last refreshed: 11 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04747717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing